Sandoz Group AG
SDZNY
Market Cap$0
Close$
$23.88
55.8% downside
Current Fair Value
55.8% downsideOvervalued by 55.8% based on the discounted cash flow analysis.
Share Statistics
| Market cap | - |
|---|---|
| Enterprise Value | - |
| Dividend Yield | $- (-%) |
| Earnings per Share | $- |
| Beta | - |
| Outstanding Shares | - |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | 0.67 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Sandoz Group AG
22,049 employees
CEO: Mr. Richard Saynor Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides prot...